Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FINASTERIDE vs PROPECIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Finasteride is a competitive 5-alpha-reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (DHT), thereby reducing DHT levels in serum and prostate tissue.
Finasteride is a competitive and specific inhibitor of type II 5α-reductase, an intracellular enzyme that converts testosterone to dihydrotestosterone (DHT). By inhibiting 5α-reductase, finasteride reduces serum and intraprostatic DHT levels, decreasing androgenic stimulation of the prostate. In hair follicles, reduction of DHT levels slows hair loss and promotes hair regrowth.
Benign prostatic hyperplasia (BPH),Male pattern baldness (androgenetic alopecia)
Treatment of male pattern hair loss (androgenetic alopecia) in men only,Treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate
1 mg orally once daily for androgenetic alopecia; 5 mg orally once daily for benign prostatic hyperplasia.
1 mg orally once daily
Terminal elimination half-life is approximately 6-8 hours (range 4-12 hours) in young adults; prolonged to ~8 hours in elderly due to reduced clearance; clinical effect on DHT suppression persists for 24 hours post-dose.
Terminal elimination half-life is approximately 6-8 hours in young adults (range 4-12 hours), with clinical relevance for once-daily dosing; slightly prolonged in elderly (8-11 hours).
Metabolized primarily via CYP3A4 in the liver; two inactive metabolites (t-butyl side chain oxidation and glucuronide conjugate).
Finasteride is extensively metabolized in the liver, primarily via the cytochrome P450 3A4 enzyme system. Two major metabolites, t-butyl side chain hydroxylation and ω-hydroxylation, have been identified; these metabolites possess less than 20% of the 5α-reductase inhibitory activity of finasteride.
Renal (39% as metabolites, <0.1% as unchanged drug); fecal (57% as metabolites); biliary elimination contributes to fecal route.
Primarily hepatic metabolism; 57% excreted in feces (as metabolites), 39% in urine (as metabolites, <0.1% as unchanged finasteride).
Approximately 93% bound to plasma proteins (primarily albumin and to a lesser extent alpha-1-acid glycoprotein).
Approximately 93% bound to plasma proteins (mainly albumin).
Volume of distribution = 76 L (approximately 1.0-1.1 L/kg), indicating extensive tissue distribution; crosses blood-brain barrier and partitions into seminal fluid.
Approximately 1.1 L/kg (range 0.9-1.3 L/kg), indicating extensive tissue distribution with penetration into seminal fluid and scalp tissue.
Oral bioavailability is approximately 63% (range 50-80%) due to incomplete absorption and first-pass metabolism; food does not significantly affect bioavailability.
Oral bioavailability is approximately 65% (range 60-70%); not affected by food.
No dose adjustment required for any level of renal impairment including end-stage renal disease.
No dose adjustment required for any degree of renal impairment
No formal studies in hepatic impairment. Caution advised; use not recommended in severe hepatic impairment due to potential accumulation. No specific Child-Pugh based dose recommendations.
No dose adjustment recommended; no studies in hepatic impairment
Not indicated in pediatric patients. Safety and efficacy not established. Avoid use in children.
Not indicated in pediatric patients; safety and efficacy not established
No age-related dose adjustment necessary. Monitor for adverse effects (e.g., sexual dysfunction, mood changes) due to potential increased sensitivity.
No specific dose adjustment; limited data in elderly men with benign prostatic hyperplasia
No FDA black box warning.
PROPECIA is not approved for use in women or children. Finasteride is contraindicated in women who are or may become pregnant due to risk of abnormalities of the external genitalia of a male fetus. Women should not handle crushed or broken tablets when pregnant or may be pregnant.
Risk of high-grade prostate cancer (decreased PSA levels may mask detection),Sexual adverse effects (e.g., decreased libido, erectile dysfunction, ejaculatory disorder) may persist after discontinuation,Increased risk of mood disturbances including depression and suicidal ideation,Not indicated for use in women or children; avoid handling crushed tablets during pregnancy due to risk to male fetus
Risk of prostate cancer: Finasteride may increase the risk of high-grade prostate cancer; digital rectal exam and PSA screening recommended before and during therapy.,Sexual dysfunction: Decreased libido, erectile dysfunction, ejaculation disorders, and decreased ejaculate volume have been reported; may persist after discontinuation.,Depression and suicidal ideation: Monitor for mood changes.,Breast cancer: Reported in men; evaluate any breast changes promptly.,Elevated PSA levels: Use caution interpreting PSA values in men on finasteride; adjust PSA levels by approximately 50% for clinical interpretation.,Hepatic impairment: Use with caution in patients with liver function abnormalities.,Pediatric use: Not indicated for use in children.
Pregnancy (category X; risk of hypospadias in male fetuses),Known hypersensitivity to finasteride or any component of the formulation
Hypersensitivity to finasteride or any component of the formulation,Women who are or may become pregnant (due to risk of hypospadias in male fetuses),Children (not indicated for use in pediatric patients)
No significant food interactions reported; finasteride may be taken with or without food. Avoid excessive alcohol consumption as it may worsen BPH symptoms or liver function.
No clinically significant food interactions. May be taken with or without food. However, avoid excessive alcohol intake as it may exacerbate certain side effects (e.g., dizziness).
Contraindicated in pregnancy. Finasteride inhibits conversion of testosterone to dihydrotestosterone, which is critical for male fetal external genitalia development. Risk of hypospadias and other urogenital malformations if exposed in utero, particularly during first trimester. Pregnancy category X.
Contraindicated in females of childbearing potential. Finasteride inhibits conversion of testosterone to DHT, and risk of hypospadias in male fetuses if exposure occurs during gestation. No adequate studies in pregnant women; animal studies show abnormal external genitalia in male offspring at doses 1-100 times human exposure.
Not recommended. Finasteride is excreted in human milk; M/P ratio not reported. Risk to nursing infant unknown, but potential for adverse effects on male infant genitalia. Use contraindicated during breastfeeding.
Not recommended. M/P ratio unknown. Finasteride is excreted in rat milk; no human data.
No dose adjustments applicable as finasteride is contraindicated in pregnancy. No pharmacokinetic studies in pregnant women due to ethical concerns.
No dose adjustments applicable as drug is contraindicated in pregnancy.
Finasteride inhibits 5α-reductase type II, reducing conversion of testosterone to DHT. Onset of effect in benign prostatic hyperplasia (BPH) requires 6-12 months; for androgenetic alopecia, 3-6 months. Serum PSA levels decrease by approximately 50% after 6 months; multiply PSA by 2 when interpreting. Avoid handling crushed or broken tablets if pregnant or planning to become pregnant due to risk of fetal genital abnormalities. Use with caution in hepatic impairment; contraindicated in women of childbearing potential, children, and patients with hypersensitivity to 5α-reductase inhibitors.
Monitor patients for sexual dysfunction (e.g., decreased libido, erectile dysfunction) which may persist after discontinuation. Finasteride lowers serum PSA by approximately 50%; when interpreting PSA values in men taking Propecia, double the measured value for prostate cancer screening. Use with caution in patients with liver impairment; hepatic metabolism is primary clearance route. Avoid handling crushed or broken tablets in women who are or may become pregnant due to risk of teratogenicity (fetal genital abnormalities). Onset of hair regrowth typically takes 3-6 months; continue use for at least 12 months before assessing efficacy.
Take finasteride exactly as prescribed, once daily with or without food.,It may take 3-6 months for hair regrowth or improvement in urinary symptoms; continue therapy as directed even if no immediate benefit is noted.,Report any breast tenderness, enlargement, or lumps; also report any new onset of sexual dysfunction (e.g., decreased libido, erectile dysfunction, ejaculation disorder).,Do not donate blood while taking finasteride and for at least 1 month after stopping, to prevent exposure to a pregnant female.,Women who are pregnant or may become pregnant should not handle crushed or broken tablets due to risk of harm to male fetus.,Serum PSA levels will decrease; inform your healthcare provider that you take finasteride before any PSA test.,Store at room temperature (20-25°C) in a dry place, away from light and moisture.
Take exactly as prescribed, usually one tablet (1 mg) daily with or without food.,Do not stop or skip doses without consulting your doctor; continuous use is needed to maintain benefit.,It may take 3-6 months to see hair regrowth and up to 12 months for full effect.,Report any new or worsening sexual side effects (e.g., decreased libido, erectile dysfunction, ejaculation disorders) promptly.,Finasteride may increase the risk of high-grade prostate cancer; discuss screening risks with your doctor.,Do not donate blood while taking Propecia and for at least 1 month after stopping to prevent exposure to pregnant women.,Women who are pregnant or may become pregnant should not handle crushed or broken tablets due to risk of birth defects.,If a dose is missed, skip it and take the next dose at the usual time; do not double up.
"Finasteride, a 5α-reductase inhibitor used for benign prostatic hyperplasia, may inhibit cytochrome P450 3A4 (CYP3A4) isoenzymes. Cyclosporine is primarily metabolized by CYP3A4. Coadministration can lead to reduced cyclosporine clearance, elevated blood concentrations, and increased risk of nephrotoxicity, hypertension, and neurotoxicity."
"Finasteride, a 5α-reductase inhibitor used for benign prostatic hyperplasia, may weakly inhibit CYP3A4, the primary enzyme responsible for sildenafil metabolism. This can lead to a modest reduction in sildenafil clearance, increasing systemic exposure and potentially enhancing both therapeutic effects and adverse events such as headache, flushing, dyspepsia, and hypotension. Clinically, this interaction is generally mild but may require dose adjustment in patients predisposed to sildenafil side effects."
"Finasteride, a 5α-reductase inhibitor, may inhibit CYP3A4-mediated metabolism of netupitant, a neurokinin-1 receptor antagonist primarily metabolized by CYP3A4. This can lead to increased netupitant plasma concentrations, potentially enhancing its adverse effects such as headache, fatigue, or dizziness. Clinically, the combination may require dose adjustment or close monitoring for netupitant toxicity."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FINASTERIDE vs PROPECIA, answered by our medical review team.
FINASTERIDE is a 5-alpha Reductase Inhibitor that works by Finasteride is a competitive 5-alpha-reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (DHT), thereby reducing DHT levels in serum and prostate tissue.. PROPECIA is a 5-alpha reductase inhibitor that works by Finasteride is a competitive and specific inhibitor of type II 5α-reductase, an intracellular enzyme that converts testosterone to dihydrotestosterone (DHT). By inhibiting 5α-reductase, finasteride reduces serum and intraprostatic DHT levels, decreasing androgenic stimulation of the prostate. In hair follicles, reduction of DHT levels slows hair loss and promotes hair regrowth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FINASTERIDE and PROPECIA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FINASTERIDE is: 1 mg orally once daily for androgenetic alopecia; 5 mg orally once daily for benign prostatic hyperplasia.. The standard adult dose of PROPECIA is: 1 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FINASTERIDE and PROPECIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FINASTERIDE is classified as Category D/X. Contraindicated in pregnancy. Finasteride inhibits conversion of testosterone to dihydrotestosterone, which is critical for male fetal external genitalia development. Risk of hypos. PROPECIA is classified as Category C. Contraindicated in females of childbearing potential. Finasteride inhibits conversion of testosterone to DHT, and risk of hypospadias in male fetuses if exposure occurs during gest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.